Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium  by Vandermeulen, Corinne et al.
D
c
t
C
H
a
b
c
d
e
a
A
R
R
A
A
K
B
V
I
S
T
a
A
A
t
p
f
s
(
h
0
lVaccine 33 (2015) 3026–3034
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
ecennial  administration  in  young  adults  of  a  reduced-antigen
ontent  diphtheria,  tetanus,  acellular  pertussis  vaccine  containing
wo  different  concentrations  of  aluminium
orinne  Vandermeulena,∗, Heidi  Theetenb, Niraj  Rathic,d, Sherine  Kuriyakosed,
tay  Htay  Hand,  Etienne  Sokale,  Karel  Hoppenbrouwersa, Pierre  Van  Dammeb
KU Leuven, University of Leuven, Centre for Environment and Health, Youth Health Care Leuven, Belgium
Centre for the Evaluation of Vaccinations, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
PATH. New Delhi, India
GlaxoSmithKline Vaccines, India and United States
Universite Catholique de Louvain, Cliniques St Luc, Pediatric Clinical Research Unit, Brussels, Belgium
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 13 August 2014
eceived in revised form 22 October 2014
ccepted 24 October 2014
vailable online 19 January 2015
eywords:
ooster
accine
mmunogenicity
afety
dpa
cellular pertussis vaccine
ntibody persistence
luminium
a  b  s  t  r  a  c  t
Background:  Regular  booster  vaccination  might  be necessary  throughout  life  to protect  against  pertussis
infection.  Nevertheless  the duration  of  protection  after  booster  vaccination  remains  unclear.  In this  study,
antibody  persistence  up  to  10  years  after previous  vaccination  of adolescents  (N  = 478) with  combined
reduced-antigen-content  diphtheria-tetanus-acellular  pertussis  vaccine  (dTpa,  BoostrixTM, GlaxoSmithK-
line  Belgium)  containing  0.5  mg, 0.3 mg or 0.133  mg  of  aluminium  was  assessed.  The  immunogenicity,
reactogenicity  and  safety  of a  decennial  booster  dTpa  dose  were  also  investigated.
Methods:  Young  adults  vaccinated  as adolescents  in  the  initial  booster  study  were  invited  to  participate
in  an  assessment  of antibody  persistence  at years  8.5 and  10,  and  to  receive  a dTpa  booster  dose  at  year  10
with immunogenicity  assessment  one  month  later. Those  who  originally  received  the  0.5 mg  or 0.3  mg
formulations  received  the  same  vaccine  at year  10. Those  in the  0.133  mg  group  received  the  0.5  mg
formulation.  Reactogenicity  and  safety  endpoints  were  captured  until  30 days  after  booster  vaccination.
Results:  Prior  to the  decennial  booster  at year 8.5  and  year  10,  all participants  had  seroprotective  anti-
bodies  for  diphtheria  (ELISA  or neutralisation  assay)  and  tetanus.  At  least  77.8%  were  seropositive  for
anti-pertussis  toxin  (PT)  antibodies  at year  8.5 and  82.8%  at year  10.  All participants  were  seropositive  for
antibodies  for  ﬁlamentous  haemagglutinin  and  pertactin  at both  time  points.  The  decennial  booster  dose
induced  robust  increases  in  antibody  GMCs  to all antigens.  The  post-booster  anti-PT  geometric  mean
concentration  was  82.5  EL.U/ml  (95%CI  67.0–101.6)  and  124.0  (103.5–148.5)  in  the  0.3  mg and  0.5  mg
groups,  respectively.  The  reactogenicity  and  safety  proﬁle  of  the  decennial  booster  dose  was  consistent
with  the  known  safety  proﬁle  of dTpa.  No serious  adverse  events  were  reported.
Conclusions:  Decennial  booster  vaccination  with  either  of  the  two licensed  formulations  of  dTpa  was
highly  immunogenic  and  well tolerated  in  young  adults.  Either  formulation  could  be conﬁdently  used  as
a decennial  booster.
This  study  is registered  at www.clinicaltrials.gov NCT01147900
©  2014  GlaxoSmithKline  and  the  Authors.  Published  by  Elsevier  Ltd.  This  is an  open  access  articleunder  the  C
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. Introduction
Routine infant vaccination against pertussis has decreased
evere disease and death due to pertussis in children, but outbreaks
ith fatal cases in infants too young to be vaccinated continue to
ccur in countries with high pertussis vaccination coverage [1,2].
either whole-cell (Pw) vaccines, acellular vaccines nor pertus-
is infection provide life-long immunity against re-infection. As
 result, Bordetella pertussis continues to circulate in vaccinated
ommunities. In older children, adolescents and adults, pertussis
ypically causes a prolonged cough illness which may  be associated
ith complications and a substantial economic cost [3,4]. Older age
roups are the primary source of pertussis transmission to infants
ho are at greatest risk of severe pertussis disease and death [5–7].
herefore, while immunization of older individuals against per-
ussis can prevent disease [8], immunization of adults may  also
revent transmission to vulnerable infants [9]. Booster vaccina-
ion of adults is achieved using combined reduced-antigen content
iphtheria-tetanus-acellular pertussis (dTpa) vaccines. While a
umber of countries recommend single pertussis booster vacci-
ations for adolescents, healthcare workers, and immunization
uring pregnancy and/or cocoon immunization, few recommend
ecennial pertussis booster doses throughout life [10].
A single serological correlate predictive of protection against
ertussis has not been identiﬁed [11], hampering estimation of the
uration of protection after pertussis booster vaccination. Decen-
ial diphtheria-tetanus (dT) booster vaccination is recommended
n many countries, and the Consensus on Pertussis Booster Vacci-
ation in Europe Initiative recommends regular pertussis boosting
f adults, achievable by replacing dT boosters with dTpa in national
chedules [12].
BoostrixTM (GlaxoSmithKline Vaccines) is a dTpa vaccine indi-
ated for booster vaccination from 4 years of age [13]. There are
wo licensed BoostrixTM formulations that differ only in aluminium
ontent: the formulation licensed in the United States contains
.3 mg  aluminium whereas the formulation licensed in Europe
nd elsewhere contains 0.5 mg.  The immunogenicity and safety
f the licensed 0.3 mg  and 0.5mg-aluminium dTpa vaccines have
een demonstrated in clinical trials in children [14,15], adoles-
ents [16–18], and adults [19,20], including adults aged ≥65 years
21,22].
The immunogenicity, reactogenicity and safety of each formu-
ation was initially established in a randomised comparative study
18] in which adolescents between 10–18 years of age who had
eceived primary vaccination against diphtheria, tetanus and Pw
ere randomised to receive a single dose of dTpa containing either
.5 mg,  0.3 mg  or 0.133 mg  aluminium. While all of the study vac-
ines were immunogenic with similar reactogenicity and safety
roﬁles, the study concluded that there was a positive effect of
luminium content on anti-pertussis toxin (PT) antibody concen-
rations [18]. In this extension study we investigated antibody
ersistence at 8.5 and 10 years after previous vaccination of ado-
escents with dTpa (0.5 mg,  0.3 mg  or 0.133 mg formulations). We
lso assessed the immunogenicity, reactogenicity and safety of a
ecennial dTpa booster dose.
. Methods
.1. Study design and participants
This open, phase IV antibody persistence and vaccination study
113055, www.clinicaltrials.gov NCT01147900) was  conducted in
hree centres in Belgium between 15 June 2010 and 8 May  2012.
tudy participants who had been vaccinated with dTpa (0.5 mg,
.3 mg  or 0.133 mg  aluminium formulations) in the previouse 33 (2015) 3026–3034 3027
booster study [18], were invited to take part in the persistence
and booster phases of this follow-up study. Antibody persistence
was assessed 8.5 years and 10 years after the ﬁrst dTpa booster
dose. Participants found to be seronegative for anti-diphtheria or
anti-tetanus antibodies at year 8.5 were to be offered a booster
dose of dTpa vaccine at that time.
A second dTpa booster dose was  administered at year 10. Par-
ticipants in the 0.5 mg  and 0.3 mg  aluminium groups received a
booster dose of the same vaccine formulation they had received 10
years earlier. Participants who  had previously received the inves-
tigational 0.133 mg  formulation received a booster dose of dTpa
containing 0.5 mg  aluminium.
The study was  conducted according to Good Clinical Practice and
the Declaration of Helsinki. The study protocol was reviewed and
approved by the ethics committees at all participating sites. Written
informed consent was  given by all participants at enrolment.
Adults were excluded from participating if they had received
booster vaccination or had experienced disease due to diphtheria,
tetanus, or pertussis since participation in the earlier study. Because
the majority of individuals had been vaccinated against meningo-
coccal disease using conjugated meningococcal vaccines, the study
protocol was  amended to allow the inclusion of subjects who had
received protein-conjugate vaccines that contained diphtheria tox-
oid (DT) or tetanus toxoid (TT) as carrier proteins. Exclusion criteria
for the booster phase are provided in the Supplementary material.
2.2. Study vaccines
The dTpa vaccines were manufactured by GlaxoSmithKline Vac-
cines. Each 0.5 ml  dose contained ≥2 international units (IU) of
DT and ≥20 IU of TT, 8 g of PT, 8 g of ﬁlamentous haemagglu-
tinin (FHA), 2.5 g of pertactin (PRN) and either 0.5 mg  or 0.3 mg
aluminium as salts, and was  preservative-free. dTpa was adminis-
tered intramuscularly into the non-dominant deltoid muscle, using
a needle at least 2.54 cm in length and 22–25 gauge.
2.3. Immunogenicity assessment
Blood samples were collected from all subjects available at years
8.5 and/or 10 for the assessment of antibody persistence. A third
blood sample was  collected one month after the booster dose. Sam-
ples were stored at −20 ◦C until shipment to GlaxoSmithKline’s
laboratories in Belgium and Quebec for testing.
Anti-diphtheria and anti-tetanus IgG antibody concentrations
were measured by ELISA with an assay cut-off of 0.1 IU/ml  [23,24].
Samples seronegative for anti-diphtheria antibodies by ELISA were
re-tested using the more sensitive in vitro neutralisation assay
on Vero cells. The cut-off for the Vero-cell assay was previ-
ously validated at 0.016 IU/ml and applied from year 8.5 onwards.
After optimization and re-validation of the assay, the cut-off was
decreased to 0.004 IU/ml, i.e., below the minimal protective thresh-
old of 0.01 IU/ml.
For diphtheria and tetanus, concentrations equal to or above
the ELISA assay cut-off were considered to be indicative of sero-
protection. Using the optimised neutralisation assay for diphtheria,
antibody concentrations of ≥0.01 IU/ml were considered to be pro-
tective [24].
Anti-PT, anti-FHA and anti-PRN IgG antibody concentrations
were measured by ELISA. The assay cut-off was  5 EL.U/ml deﬁning
seropositivity [25,26].2.4. Assessment of reactogenicity and safety
The occurrence of redness, swelling and pain at the injection site,
and fatigue, fever (temperature ≥37.5 ◦C, oral or axillary routes),
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astrointestinal symptoms and headache, was recorded on the day
f vaccination and for three subsequent days (4-day follow-up).
Participants with large swelling reactions (diameter >100 mm,
iffuse swelling or noticeable increase in limb circumference) at
he injection site were asked to contact study personnel and return
o the study centre for assessment. All other adverse events (AEs)
ere recorded for 30 days after vaccination (31-day follow up).
erious adverse events (SAEs) related to study participation or to
ny GlaxoSmithKline medication, and all fatal SAEs were recorded
uring the entire study period. All local symptoms were considered
o be vaccine related. The investigator assessed the relationship of
ll other symptoms to vaccination.
.5. Statistical analyses
Analyses were performed using SAS® software version 9.2 (SAS
nstitute Inc., Cary, NC, United States) and StatXact-8.1 procedure
n SAS®.
The primary analysis of antibody persistence at year 8.5
as done on the according-to-protocol (ATP) persistence cohort,
hich included eligible participants with serological results
vailable at year 8.5. The analysis of persistence and booster
mmunogenicity at year 10 was conducted on the year 10 ATP
mmunogenicity cohort, which included eligible participants with
erological results available at the one-month post-booster time
oint.
Seroprotection/seropositivity rates were calculated for each
reatment group with exact 95% conﬁdence intervals (CI). Booster
esponse (BR) rates to pertussis antigens were calculated using
wo pre-deﬁned deﬁnitions (see Table 3 footnote) used in previous
tudies of dTpa (note that different deﬁnitions of a booster response
re accepted in the United States as compared to other countries).
esults according to both deﬁnitions are provided for ease of com-
arison with other studies. Additional longitudinal analyses were
onducted using repeated measurement technique on immuno-
enicity data obtained between the two booster vaccinations in
rder to evaluate potential bias related to missing data.t ﬂow.
3. Results
3.1. Study subjects
Of 478 adolescents who participated in the booster study 10
years previously, 180 returned at year 8.5, and 177 returned and
were vaccinated at year 10 (Fig. 1). Treatment groups were similar
in age at each follow-up time point (Table 1).
By year 10, 77.4% (n = 137) of participants had received vac-
cination with a CRM (modiﬁed diphtheria toxoid)-conjugated
meningococcal vaccine and 7.9% (n = 14) had received a TT-
conjugated meningococcal vaccine since the initial dTpa booster
dose. Most meningococcal vaccines were given 1 month after the
initial dTpa study vaccination (at the time of blood sampling).
The most common reasons for non-participation in this exten-
sion study were: lost to follow-up (n = 92), unwilling to participate
(not due to an AE, n = 88) or ineligible (n = 30). No participant
required a booster dose of dTpa at year 8.5.
3.2. IgG antibody persistence at year 8.5 and year 10
Except for one participant in the dTpa-0.3 group, all other
study participants had anti-diphtheria concentrations ≥0.1 IU/ml
by ELISA at year 8.5, with no change observed at year 10. The
single participant with ELISA concentrations ≤0.1 IU/ml was sero-
protected at each time point as assessed using the in vitro
neutralisation assay (Table 2).
The percentage of participants with anti-diphtheria concentra-
tions ≥1.0 IU/ml decreased between year 8.5 and year 10 in each
treatment group, and was 59.3% in the dTpa-0.133 group, 44.4%
in the dTpa-0.3 group, and 33.3% in the dTpa-0.5 group at year
10 (Table 2). Anti-diphtheria GMCs also decreased over time but
remained higher than levels prior to the ﬁrst dTpa dose (Fig. 2).All participants maintained anti-tetanus concentrations of
≥0.1 IU/ml until year 10. The percentage with anti-tetanus concen-
trations ≥1.0 IU/ml ranged between 84.7% and 88.9% in each group
at years 8.5 and 10. Anti-tetanus antibody GMCs were similar at
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Table  1
Demographic characteristics (ATP cohort for persistence at year 8.5 and ATP immunogenicity cohort at year 10).
Year 8.5 Year 10
dTpa-0.3 N = 54 dTpa-0.133 N = 59 dTpa-0.5 N = 65 dTpa-0.3 N = 54 dTpa-0.133 N = 59 dTpa-0.5 N = 60
Age (years) Mean (SD) 22.4 (1.46) 22.3 (1.21) 22.3 (1.18) 23.5 (1.45) 23.4 (1.21) 23.4 (1.15)
Range  20–27 19–27 19–25 20–28 20–28 20–26
Female n (%) 29 (53.7) 33 (55.9) 39 (60.0) 28 (51.9) 30 (50.8) 35 (58.3)
26
S
y
b
b
T
A
nGender
Male  n (%) 25 (46.3) 26 (44.1)
D = standard deviation.
ears 8.5 and 10, but were lower than levels observed after the ﬁrst
ooster dose (Fig. 2).
In each treatment group, seropositivity rates for anti-PT anti-
odies before the decennial booster dose were between 82.8% and
able 2
ntibody persistence (ELISA) to year 10 and immunogenicity of the booster dose (ATP co
Antibody Group Timing Na
Anti-diphtheria dTpa-0.3 Year 8.5 54 
Year  10 pre 54 
Year  10 post 54 
dTpa-0.133 Year 8.5 59 
Year  10 Pre 59 
Year  10 post 59 
dTpa-0.5 Year  8.5 65 
Year  10 pre 60 
Year  10 post 60 
Anti-Tetanus dTpa-0.3 Year 8.5 54 
Year  10 pre 54 
Year  10 post 54 
dTpa-0.133 Year 8.5 59 
Year  10 Pre 59 
Year  10 post 59 
dTpa-0.5 Year  8.5 65 
Year  10 pre 60 
Year  10 post 60 
≥5  EL.U/ml 
Anti-PT dTpa-0.3 Year 8.5 54 
Year  10 pre 52 
Year  10 post 54 
dTpa-0.133 Year 8.5 59 
Year  10 pre 58 
Year  10 post 59 
dTpa-0.5 Year  8.5 65 
Year  10 pre 58 
Year  10 post 60 
Anti-FHA dTpa-0.3 Year 8.5 54 
Year  10 pre 54 
Year  10 post 53 
dTpa-0.133 Year 8.5 59 
Year  10 pre 59 
Year  10 post 59 
dTpa-0.5 Year 8.5 62 
Year  10 pre 59 
Year 10 post 60 
Anti-PRN dTpa-0.3 Year 8.5 54 
Year  10 pre 54 
Year  10 post 53 
dTpa-0.133 Year 8.5 59 
Year  10 pre 59 
Year  10 post 59 
dTpa-0.5 Year 8.5 65 
Year  10 pre 59 
Year  10 post 60 
a N = number of subjects with both pre- and post-vaccination results available.
b n/% = number/percentage of subjects which reached cut-off level.
c 95% CI = Exact 95% conﬁdence interval.
d one subject seronegative for anti-diphtheria antibodies by ELISA had antibodies ≥0.0
eutralisation assay. (40.0) 26 (48.1) 29 (49.2) 25 (41.7)
86.2%, while all participants remained seropositive for antibodies
for FHA and PRN (Table 2). GMCs for PT, FHA and PRN all decreased
over time after the initial booster dose (Fig. 2). Consistent with ﬁnd-
ings after the ﬁrst dTpa dose 10 years earlier, the persisting anti-PT
hort for persistence at year 8.5 and ATP immunogenicity cohort at year 10).
≥0.1 IU/ml ≥1.0 IU/ml
Nb % (95% CI)c Nb % (95% CI)
53d 98.1 (90.1; 100) 29 53.7 (39.6; 67.4)
53d 98.1 (90.1; 100) 24 44.4 (30.9; 58.6)
54 100 (93.4; 100) 54 100 (93.4; 100)
59 100 (93.9; 100) 41 69.5 (56.1; 80.8)
59 100 (93.9; 100) 35 59.3 (45.7; 71.9)
59 100 (93.9; 100) 58 98.3 (90.9; 100)
65 100 (94.5; 100) 26 40.0 (28.0; 52.9)
60 100 (94.0; 100) 20 33.3 (21.7; 46.7)
60 100 (94.0; 100) 60 100 (94.0; 100)
54 100 (93.4; 100) 48 88.9 (77.4; 95.8)
54 100 (93.4; 100) 47 87.0 (75.1; 94.6)
54 100 (93.4; 100) 54 100 (93.4; 100)
59 100 (93.9; 100) 50 84.7 (73.0; 92.8)
59 100 (93.9; 100) 51 86.4 (75.0; 94.0)
59 100 (93.9; 100) 58 98.3 (90.9; 100)
65 100 (94.5; 100) 57 87.7 (77.2; 94.5)
60 100 (94.0; 100) 52 86.7 (75.4; 94.1)
60 100 (94.0; 100) 60 100 (94.0; 100)
≥20 EL.U/ml
42 77.8 (64.4; 88.0) –
44 84.6 (71.9; 93.1) 17 32.7 (20.3; 47.1)
54 100 (93.4; 100) 54 100 (93.4; 100)
48 81.4 (69.1; 90.3) –
48 82.8 (70.6; 91.4) 24 41.4 (28.6; 55.1)
59 100 (93.9; 100) 58 98.3 (90.9; 100)
60 92.3 (83.0; 97.5) –
50 86.2 (74.6; 93.9) 25 43.1 (30.2; 56.8)
60 100 (94.0; 100) 60 100 (94.0; 100)
54 100 (93.4; 100) –
54 100 (93.4; 100) 53 98.1 (90.1; 100)
53 100 (93.3; 100) 53 100 (93.3; 100)
59 100 (93.9; 100) –
59 100 (93.9; 100) 58 98.3 (90.9; 100)
59 100 (93.9; 100) 59 100 (93.9; 100)
62 100 (94.2; 100) –
59 100 (93.9; 100) 59 100 (93.9; 100)
60 100 (94.0; 100) 60 100 (94.0; 100)
54 100 (93.4; 100) –
54 100 (93.4; 100) 52 96.3 (87.3; 99.5)
53 100 (93.3; 100) 53 100 (93.3; 100)
59 100 (93.9; 100) –
59 100 (93.9; 100) 58 98.3 (90.9; 100)
59 100 (93.9; 100) 59 100 (93.9; 100)
65 100 (94.5; 100) –
59 100 (93.9; 100) 57 96.6 (88.3; 99.6)
60 100 (94.0; 100) 60 100 (94.0; 100)
16 IU/ml at year 8.5 and≥0.01 IU/ml at year 10 when re-tested using the in vitro
3030 C. Vandermeulen et al. / Vaccine 33 (2015) 3026–3034
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ohort) and those who  received the decennial booster dose (year 10 ATP immunog
ootnote: vertical lines indicate 95% CIs.
MCs at years 8.5 and 10 were observed to be numerically higher
n the dTpa-0.5 group.
.2.1. Sensitivity analysis
GMCs estimated at years 8.5 and 10 using the repeated mea-
urements model were close to observed values in each treatment
roup (data not shown). This indicates that the analyses of antibody
ersistence performed at years 8.5 and 10 were not unduly affected
y subjects who dropped out.
.3. Response to booster vaccinationOne month after the decennial dTpa booster dose all participants
ad anti-diphtheria and anti-tetanus concentrations ≥0.1 IU/ml,
nd between 98.3% and 100% had concentrations ≥1.0 IU/mlrticipated in the initial booster vaccination study (study 029 ATP immunogenicity
 cohort).
(Table 2). In each group, anti-diphtheria and anti-tetanus GMCs
increased between 3.8- and 6.0-fold.
All participants were seropositive for anti-PT antibodies one
month after the booster dose (Table 2). In each group GMCs
increased by 5.7- and 7.9-fold for anti-PT and anti-FHA, respec-
tively, and between 2.8- and 3.9-fold for anti-PRN antibodies.
The post-booster anti-PT geometric mean concentration was
82.5 EL.U/ml (95% CI 67.0–101.6) in the 0.3 mg  group 108.1 (95% CI
87.7–133.2) in the 0.133 mg  group and 124.0 (95% CI 103.5–148.5)
in the 0.5 mg  group, reaching numerically higher GMC  levels com-
pared to the ﬁrst booster dose in the 0.133 mg and 0.5 mg  groups
(Fig. 2).Using deﬁnition 1, a BR for PT or FHA was observed in at least
90.4% of participants in each group, including all participants who
were initially seronegative for anti-PT antibodies (Table 3). For
PRN, a BR was  observed in 51.1% of participants in the dTpa-0.3
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Table  3
Pertussis booster response rates after dTpa booster vaccination at year 10 (ATP immunogenicity cohort).
Antibody Group Na Nb % (95% CI)
Deﬁnition 1c
Anti-PT dTpa-0.3 44 44 100 (92.0; 100)
dTpa-0.133 51 51 100 (93.0; 100)
dTpa-0.5 51 48 94.1 (83.8; 98.8)
Anti-FHA dTpa-0.3 46 43 93.5 (82.1; 98.6)
dTpa-0.133 52 47 90.4 (79.0; 96.8)
dTpa-0.5 50 48 96.0 (86.3; 99.5)
Anti-PRN dTpa-0.3 45 23 51.1 (35.8; 66.3)
dTpa-0.133 52 29 55.8 (41.3; 69.5)
dTpa-0.5 52 35 67.3 (52.9; 79.7)
Deﬁnition 2d
Anti-PT dTpa-0.3 44 40 90.9 (78.3; 97.5)
dTpa-0.133 51 47 92.2 (81.1; 97.8)
dTpa-0.5 51 48 94.1 (83.8; 98.8)
Anti-FHA dTpa-0.3 46 43 93.5 (82.1; 98.6)
dTpa-0.133 52 47 90.4 (79.0; 96.8)
dTpa-0.5 50 48 96.0 (86.3; 99.5)
Anti-PRN dTpa-0.3 45 23 51.1 (35.8; 66.3)
dTpa-0.133 52 29 55.8 (41.3; 69.5)
dTpa-0.5 52 35 67.3 (52.9; 79.7)
a N = number of subjects with both pre- and post-vaccination results available.
b N/% = number/percentage of subjects with a booster response
c Deﬁnition 1: the appearance of antibodies in participants who were seronegative prior to the booster dose, or a ≥2-fold increase in concentration in initially seropositive
participants.
d Deﬁnition 2: a ≥4-fold increase (post-booster antibody concentration ≥20 EL.U/ml) in initially seronegative participants, a ≥4-fold increase in initially seropositive
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darticipants with a pre-booster antibody concentration ≥5 EL.U/ml and <20 EL.U/ml
oncentration ≥20 EL.U/ml.
roup 55.8%, in the dTpa-0.133 group and 67.3% in the dTpa-0.5
roup.
Similar trends were observed using deﬁnition 2 (Table 3), with
Rs for PT or FHA observed in at least 90.4% of participants
including all initially seronegative subjects), and in 51.1%–67.3%
f participants for PRN.
.4. Safety
Pain at the injection site was the most frequently reported local
ymptom, reported by 87.1%–93.2% of vaccinees in each group
Table 4). Grade 3 local symptoms (see Table 4 footnote for grade 3
eﬁnitions) were reported by not more than ﬁve participants in
ny group. One participant (dTpa-0.133 group) reported a large
welling reaction with onset 3 days after the booster dose. The
welling was conﬁned to the injection site and resolved after 2 days.
The most frequently reported systemic symptoms in each
roup were fatigue (31.5%–35.5% of vaccinees) and headache
21.0%–32.2%) (Table 4). Fever (all <39 ◦C) was reported by one par-
icipant (<2.0%) in each treatment group. Grade 3 solicited systemic
ymptoms considered to be related to vaccination were reported by
ot more than three vaccinees in each group (Table 4). No solicited
ocal or general symptoms resulted in a medically attended visit.
At least one AE occurring within 31 days after vaccination con-
idered by the investigator to be related to vaccination was reported
y 12.7% (95% CI 5.3;24.5) of participants in the dTpa-0.3 group,
1.7% (4.8;22.6) in the dTpa-0.133 group and 14.5% (6.9;25.8) in
he dTpa-0.5 group. Vaccine-related AEs reported at least twice in
ny group were injection site induration, injection site pruritus,
rthralgia and myalgia. No related AEs were reported by more than
wo participants in any group. No SAEs were reported during the
ntire study period.
Reactogenicity and safety in this and the previous booster study
ere assessed using identical methods. The incidence of local and
olicited symptoms after the decennial booster dose was similar or
ower to that observed in the same subjects after the ﬁrst booster
ose 10 years previously (Table 4).a ≥2-fold increase in initially seropositive participants with a pre-booster antibody
4. Discussion
We previously reported that a booster dose of dTpa contain-
ing 0.133 mg,  0.3 mg  or 0.5 mg  aluminium administered to healthy
adolescents primed in infancy with DTPw, induced robust BRs
to all vaccine antigens [18]. In the present study conducted 10
years later, all returning participants continued to have seroprotec-
tive antibodies for diphtheria and tetanus (using ELISA or in vitro
neutralisation assay), at least 82.8% were seropositive for anti-
PT antibodies and all participants were seropositive for anti-FHA
and anti-PRN antibodies. In our cohort, anti-pertussis antibodies
appeared to persist longer after the ﬁrst dTpa dose than after Pw-
primary vaccination. Furthermore, antibodies to PT, FHA and PRN
appeared to be higher 10 years after the ﬁrst dTpa booster than
observed in children after infant vaccination with acellular pertus-
sis vaccines [27,28].
A positive association between aluminium content of the dTpa
vaccine and the anti-PT antibody response observed after the ini-
tial booster vaccination continued to be observed up to 10 years
later, with a numerically higher anti-PT antibody seropositivity rate
and GMC  in the dTpa-0.5 group. In view of the robust response to
PT at both time points, these results are unlikely to be of clinical
importance.
A decennial booster dose induced robust increases in antibody
GMCs for all antigens. Post-booster anti-diphtheria and anti-PT
GMCs were similar to levels achieved after the ﬁrst booster dose
10 years previously, whereas GMCs for tetanus, FHA and PRN
were lower than after the previous booster, possibly reﬂecting the
higher pre-vaccination concentrations at the time of the second
booster dose compared to the ﬁrst. Indeed, similar trends have been
observed in other studies that assessed a decennial dTpa booster
vaccination [29,30]. In these studies, high pre-booster concentra-
tions were associated with lower booster rates and post-booster
GMCs.
The reactogenicity and safety proﬁle of the decennial booster
dose was in line with the known safety proﬁle of BoostrixTM, which
is characterised by early onset of short-lived symptoms at the
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Table 4
Incidence of solicited general symptoms reported within 4 days after the ﬁrst dTpa booster dose, and after the decennial dTpa booster dose in subjects who received the decennial booster dose (Total vaccinated cohorts).
First dTpa booster dose 10 years earlier Decennial dTpa booster dose (present study)
dTpa-0.3 N = 55a dTpa-0.133 N = 59 dTpa-0.5 N = 62 dTpa-0.3 N = 54–55a dTpa-0.133 N = 59 dTpa-0.5 N = 62
nb % (95% CI) c n % (95% CI) n % (95% CI) nb % (95% CI) c n % (95% CI) n % (95% CI)
Pain Any 52 94.5 (84.9; 98.9) 54 91.5 (81.3; 97.2) 59 95.2 (86.5; 99.0) 50 90.9 (80.0; 97.0) 55 93.2 (83.5; 98.1) 54 87.1 (76.1; 94.3)
Grade  3 7 12.7 (5.3; 24.5) 7 11.9 (4.9; 22.9) 6 9.7 (3.6; 19.9) 2 3.6 (0.4; 12.5) 5 8.5 (2.8; 18.7) 3 4.8 (1.0; 13.5)
Redness  (mm) Any 22 40.0 (27.0; 54.1) 15 25.4 (15.0; 38.4) 17 27.4 (16.9; 40.2) 23 41.8 (28.7; 55.9) 23 39.0 (26.5; 52.6) 21 33.9 (22.3; 47.0)
≥50  mm 10  18.2 (9.1; 30.9) 6 10.2 (3.8; 20.8) 2 3.2 (0.4; 11.2) 2 3.6 (0.4; 12.5) 0 0.0 (0.0; 6.1) 2 3.2 (0.4; 11.2)
Swelling  (mm) Any 18 32.7 (20.7; 46.7) 16 27.1 (16.4; 40.3) 23 37.1 (25.2; 50.3) 21 38.2 (25.4; 52.3) 20 33.9 (22.1; 47.4) 19 30.6 (19.6; 43.7)
≥50  mm 7 12.7 (5.3; 24.5) 4 6.8 (1.9; 16.5) 8 12.9 (5.7; 23.9) 3 5.5 (1.1; 15.1) 3 5.1 (1.1; 14.1) 1 1.6 (0.0; 8.7)
Fatigue Any  20 37.0 (24.3; 51.3) 23 39.0 (26.5; 52.6) 24 38.7 (26.6; 51.9) 17 31.5 (19.5; 45.6) 20 33.9 (22.1; 47.4) 22 35.5 (23.7; 48.7)
Grade  3d Relatede 3 5.6 (1.2; 15.4) 2 3.4 (0.4; 11.7) 3 4.8 (1.0; 13.5) 0 0.0 (0.0; 6.6) 0 0.0 (0.0; 6.1) 2 3.2 (0.4; 11.2)
Gastrointestinal Any  7 13.0 (5.4; 24.9) 9 15.3 (7.2; 27.0) 11 17.7 (9.2; 29.5) 10 18.5 (9.3; 31.4) 9 15.3 (7.2; 27.0) 13 21.0 (11.7; 33.2)
Grade  3d Relatede 1 1.9 (0.0; 9.9) 1 1.7 (0.0; 9.1) 1 1.6 (0.0; 8.7) 1 1.9 (0.0; 9.9) 1 1.7 (0.0; 9.1) 3 4.8 (1.0; 13.5)
Headache Any  23 42.6 (29.2; 56.8) 25 42.4 (29.6; 55.9) 30 48.4 (35.5; 61.4) 13 24.1 (13.5; 37.6) 19 32.2 (20.6; 45.6) 13 21.0 (11.7; 33.2)
Grade  3d Relatede 0 0.0 (0.0; 6.6) 2 3.4 (0.4; 11.7) 2 3.2 (0.4; 11.2) 1 1.9 (0.0; 9.9) 0 0.0 (0.0; 6.1) 1 1.6 (0.0; 8.7)
Temperature Any  5 9.3 (3.1; 20.3) 4 6.8 (1.9; 16.5) 9 14.5 (6.9; 25.8) 1 1.9 (0.0; 9.9) 1 1.7 (0.0; 9.1) 1 1.6 (0.0; 8.7)
>39.0 ◦C Relatede 0 0.0 (0.0; 6.6) 0 0.0 (0.0; 6.1) 0 0.0 (0.0; 5.8) 0 0.0 (0.0; 6.6) 0 0.0 (0.0; 6.1) 0 0.0 (0.0; 5.8)
a N = with at least one documented dose, respectively.
b n/% = number/percentage of subjects who  reported the symptom at least once.
c 95% CI = exact 95% conﬁdence interval.
d Grade 3: symptoms that prevent normal activity.
e Related = symptoms considered by the investigator to be vaccine-related
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[7] Edwards KM. Overview of pertussis: focus on epidemiology, sources of infec-
tion, and long term protection after infant vaccination. Pediatr Infect Dis J
2005;24:S104–8.C. Vandermeulen et al. / 
njection site and few severe systemic reactions. The reactogenic-
ty proﬁle of the decennial dose resembled that of the booster
dministered 10 years previously.
While this study was not designed or powered to compare the
mmunogenicity and safety of the 0.5 mg  and 0.3 mg  formulations,
e observed no marked differences in the immunogenicity or reac-
ogenicity proﬁles when either vaccine was administered 10 years
part. While the observed post-booster GMC  for PT was  highest
n the dTpa-0.5 group (124.0 EL.U/ml) and lowest in the dTpa-0.3
roup (82.5 EL.U/ml), BR rates and seropositivity rates were sim-
lar. Interestingly, while the lowest anti-PT antibody GMCs were
bserved in the dTpa-0.133 group after the initial vaccination,
ecennial boosting with the dTpa-0.5 formulation ‘corrected’ the
esponse to a level between the dTpa-0.3 and dTpa-0.5 groups. At
ach time point anti-diphtheria GMCs appeared to be negatively
ssociated with aluminium content, although the small sample size
recludes ﬁrm conclusions and this is likely of little clinical impor-
ance in view of the high levels of seroprotection to diphtheria in
ll groups over time.
The data suggest a small but consistent negative effect of lower
luminium content on anti-PT GMCs that appears to have minimal
linical consequences if a booster is given, in view of the robust
esponses observed. Within the limits of the study, use of dTpa
ontaining either 0.5 mg  or 0.3 mg  aluminium does not appear to
e associated with any clinically important difference in clinical
rotection, reactogenicity or safety.
Our study was limited by around 63% drop out of the originally
accinated cohort and the sample size was thus too small to per-
orm statistical comparisons between groups. Our study was also
imited in that around 85% participants had received a conjugated
eningococcal vaccine. Immune responses to the carrier protein
ay  have elevated anti-diphtheria and anti-tetanus antibodies in
he analysis of persistence. However, since most meningococcal
accination occurred shortly after the ﬁrst dTpa dose (a meningo-
occal C vaccination campaign in Flanders during the study period
argeted the age group invited for the booster study [31,32]), any
ffect on the decennial booster is likely to be minimal.
Our results compare favourably with earlier evaluations of a
ecennial dTpa booster dose after initial vaccination in 10–14
ear olds [30] and in adults ≥18 years of age [29]. Pertussis will
ltimately be controlled or potentially eliminated if improved
accines that induce a more potent immune response are devel-
ped and widely used. Until this time, regular, decennial booster
accination of adults appears to be a feasible means by which
o reduce pertussis circulation and disease in highly vaccinated
opulations.
Decennial vaccination using two formulations of dTpa vaccine
as highly immunogenic and well tolerated in young adults. Either
ormulation could be conﬁdently used as a decennial booster.
BOOSTRIX is a trademark of the GlaxoSmithKline group of com-
anies.
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